---
title: "HITECK released its performance for the first three quarters, with a net loss attributable to the parent company of 158 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262252868.md"
description: "According to the Zhitong Finance APP, HITECK released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 422 million yuan, a year-on-year decrease of 6.45%. The net loss attributable to shareholders of the listed company was 158 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 180 million yuan. The basic loss per share was 1.21 yuan"
datetime: "2025-10-22T12:54:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262252868.md)
  - [en](https://longbridge.com/en/news/262252868.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262252868.md)
---

# HITECK released its performance for the first three quarters, with a net loss attributable to the parent company of 158 million yuan

According to the Zhitong Finance APP, HITECK (300683.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 422 million yuan, a year-on-year decrease of 6.45%. The net loss attributable to shareholders of the listed company was 158 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 180 million yuan. The basic loss per share was 1.21 yuan

### Related Stocks

- [300683.CN](https://longbridge.com/en/quote/300683.CN.md)

## Related News & Research

- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [Coffee Prices Rebound on Technical Short-Covering](https://longbridge.com/en/news/286941721.md)
- [Dunkin' To Give Away 1 Mln Free Coffees For A Day](https://longbridge.com/en/news/286964019.md)
- [20:38 ETHyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"](https://longbridge.com/en/news/287135394.md)
- [Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO](https://longbridge.com/en/news/286972125.md)